NO20062741L - Surfaktantbasert gel som en injiserbar, vedvarende leveringsvehikkel - Google Patents

Surfaktantbasert gel som en injiserbar, vedvarende leveringsvehikkel

Info

Publication number
NO20062741L
NO20062741L NO20062741A NO20062741A NO20062741L NO 20062741 L NO20062741 L NO 20062741L NO 20062741 A NO20062741 A NO 20062741A NO 20062741 A NO20062741 A NO 20062741A NO 20062741 L NO20062741 L NO 20062741L
Authority
NO
Norway
Prior art keywords
surfactant
solvent
sustained delivery
injectable
gel
Prior art date
Application number
NO20062741A
Other languages
English (en)
Norwegian (no)
Inventor
Luk Andrew Sheung-King
Stan Lam
Zhang Yuan Peng
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO20062741L publication Critical patent/NO20062741L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20062741A 2003-11-14 2006-06-13 Surfaktantbasert gel som en injiserbar, vedvarende leveringsvehikkel NO20062741L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51998903P 2003-11-14 2003-11-14
US10/985,228 US20050118206A1 (en) 2003-11-14 2004-11-10 Surfactant-based gel as an injectable, sustained drug delivery vehicle
PCT/US2004/037782 WO2005048930A2 (en) 2003-11-14 2004-11-12 Surfactant-based gel as an injectable, sustained drug delivery vehicle

Publications (1)

Publication Number Publication Date
NO20062741L true NO20062741L (no) 2006-08-14

Family

ID=34623115

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062741A NO20062741L (no) 2003-11-14 2006-06-13 Surfaktantbasert gel som en injiserbar, vedvarende leveringsvehikkel

Country Status (12)

Country Link
US (1) US20050118206A1 (pt)
EP (1) EP1691715A4 (pt)
JP (1) JP2007511525A (pt)
KR (1) KR20070001876A (pt)
AU (1) AU2004291094A1 (pt)
BR (1) BRPI0416038A (pt)
CA (1) CA2545800A1 (pt)
IL (1) IL175599A0 (pt)
MX (1) MXPA06005465A (pt)
NO (1) NO20062741L (pt)
TW (1) TW200526252A (pt)
WO (1) WO2005048930A2 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DE602004012081T2 (de) 2003-03-31 2009-03-19 Intarcia Therapeutics, Inc., Emeryville Osmotische pumpe mit mitteln zum ableiten des innendrucks
CN1767815A (zh) 2003-03-31 2006-05-03 阿尔萨公司 非水单相载体和使用这类载体的制剂
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
KR101341359B1 (ko) * 2004-10-01 2013-12-13 램스코르 인코포레이티드 편리하게 이식가능한 서방형 약물 조성물
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) * 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
US8703195B2 (en) * 2006-03-10 2014-04-22 Biorem Ag Method for solubilising, dispersing and stabilising of substances, products manufactured according to the method as well as the use thereof
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
WO2008092084A2 (en) * 2007-01-26 2008-07-31 Centocor, Inc. Injectable non-aqueous suspension with high concentration of therapeutic agent
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US20110144010A1 (en) * 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
TW201010708A (en) * 2008-06-02 2010-03-16 Intervet Int Bv Composition comprising an antibiotic and a corticosteroid
US8846770B2 (en) * 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
WO2011075623A1 (en) * 2009-12-18 2011-06-23 Latitude Pharmaceuticals, Inc. One - phase gel compos ition compri s ing phos pholi pids
CA2786953A1 (en) * 2010-01-12 2011-07-21 Florian Anders Foeger Pharmaceutical compositions for oral administration of insulin peptides
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
KR101805087B1 (ko) * 2010-09-16 2017-12-05 주식회사 엘지화학 높은 방부력을 제공하는 오일 주사 제형
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
AU2012225268B2 (en) * 2011-03-10 2016-10-20 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
EP2846773A4 (en) * 2012-05-10 2015-12-30 Painreform Ltd DEPOT FORMULATIONS OF A LOCAL ANESTHETICS AND METHOD FOR THE MANUFACTURE THEREOF
KR101586791B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2730996C2 (ru) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Системы установки и извлечения имплантата
WO2017105512A1 (en) 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
PE20210857A1 (es) 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
US20180256622A1 (en) * 2017-03-10 2018-09-13 Piedmont Animal Health, Llc Injectable antibiotic formulations and use thereof
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4371519A (en) * 1972-06-05 1983-02-01 Hettinger Jr William P Methods of treating cellular tissue
US4255415A (en) * 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5266326A (en) * 1992-06-30 1993-11-30 Pfizer Hospital Products Group, Inc. In situ modification of alginate
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
CA2150803C (en) * 1992-12-02 2006-01-31 Henry Auer Controlled release growth hormone containing microspheres
JPH09507233A (ja) * 1993-12-29 1997-07-22 マトリクス ファーマスーティカル，インコーポレイティド 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5599534A (en) * 1994-08-09 1997-02-04 University Of Nebraska Reversible gel-forming composition for sustained delivery of bio-affecting substances, and method of use
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
JP4642946B2 (ja) * 1996-12-20 2011-03-02 アルザ コーポレイション ゲル組成物および方法
US5993374A (en) * 1997-06-17 1999-11-30 Radiance Medical Systems, Inc. Microcapsules for site-specific delivery
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
CA2361424C (en) * 1999-02-08 2009-04-28 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
AU2001271491A1 (en) * 2000-06-26 2002-01-08 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6991809B2 (en) * 2001-06-23 2006-01-31 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
DE60239952D1 (de) * 2001-11-14 2011-06-16 Durect Corp Injizierbare depotzusammensetzungen und deren verwendung

Also Published As

Publication number Publication date
EP1691715A2 (en) 2006-08-23
AU2004291094A1 (en) 2005-06-02
BRPI0416038A (pt) 2007-01-02
IL175599A0 (en) 2008-04-13
KR20070001876A (ko) 2007-01-04
US20050118206A1 (en) 2005-06-02
JP2007511525A (ja) 2007-05-10
WO2005048930A3 (en) 2005-08-04
WO2005048930A2 (en) 2005-06-02
CA2545800A1 (en) 2005-06-02
EP1691715A4 (en) 2007-09-26
MXPA06005465A (es) 2006-08-11
TW200526252A (en) 2005-08-16

Similar Documents

Publication Publication Date Title
NO20062741L (no) Surfaktantbasert gel som en injiserbar, vedvarende leveringsvehikkel
BR0316310A (pt) Composições farmacêuticas tendo um veìculo modificado
NO20061926L (no) Gellignende og skummende sammensetninger med hoyt alkoholinnhold
BRPI0601896A (pt) composições que contêm microgéis e agentes espessantes
ATE229568T1 (de) Stabilisierte flüssige enzymzusammensetzungen
PE20100265A1 (es) Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
WO2008152444A3 (en) Foamable waterless compositions with modulating agents
AR037251A1 (es) Composiciones limpiadoras y desinfectantes para superficies duras y proceso para la limpieza e higienizacion de una superficie dura
PE20060003A1 (es) Formulacion farmaceutica polimerica para moldear por inyeccion
BR0001399A (pt) Processo para melhoria de estabilidade de viscosidade de uma composição aquosa, e composição
RU2011107878A (ru) Гели на основе гиалуроновой кислоты, включающие обезболивающие агенты
KR960705541A (ko) 로테프레드놀 에타보네이트의 현탁액(suspension of loteprednol etabonate)
BR0108449A (pt) Formulações de pasta aperfeiçoada
DE502004009461D1 (de) Stabilisierung von wasserstoffperoxid während der sserstoffperoxidhaltigen systemen
CO5440227A1 (es) Composicion antihelmitica e inyectable mejorada de crecimiento
PE20021147A1 (es) Composicion de alimento para mascotas que contiene agentes de gelacion semi-refinados
ATE526390T1 (de) Hochkonzentrierte tensidzusammensetzungen und verfahren
BR112015013689A2 (pt) composições fluidas de cuidado oral contendo peróxido
WO2006118594A3 (en) Oxydizing compositions and methods thereof
WO2019215679A8 (en) Foam sanitizer composition
MX2025006791A (es) Agente de iarn con nucleótidos modificados
BR0215303A (pt) Formulações farmacêuticas de base aquosa de pró-drogas solúveis em água de propofol
MX2021008264A (es) Aditivo y mezcla para composiciones cementosas, composiciones cementosas, estructuras cementosas y metodos para preparar los mismos.
ATE395084T1 (de) Bioadhäsives gel auf basis von hydroxyethylcellulose
CO5690526A2 (es) Composiciones para acondicionamiento del cabello

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application